Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder

This study has been completed.
Sponsor:
Collaborators:
Stanley Medical Research Institute
GlaxoSmithKline
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00226135
First received: September 23, 2005
Last updated: April 4, 2007
Last verified: April 2007

September 23, 2005
April 4, 2007
March 2001
Not Provided
Time to a new mood episode after having succeeded the first 6 month of treatment and reached monotherapy with study drug at that point. New episode defined as symptoms requiring treatment or admission (or suicide).
Same as current
Complete list of historical versions of study NCT00226135 on ClinicalTrials.gov Archive Site
  • 1: number of patients (ITT population)that completed first 6 months and achieved monotherapy at that time.
  • 2: Number of patients with reported AE (type specified)
  • 3: Number of patients with an endpoint other than censoring (among populations under observation for ½ year, 1 year, 1½ years, 2 years, and 2½ years)
  • 4:The primary end point but selected to patients under observations for 1½ and 2½ years
  • 5: Number of endpoint (other than censoring)among patients reaching 6 months and monotherapy at that time, per person-time(testing for inter-group balance with respect to background variables)
Same as current
Not Provided
Not Provided
 
Prophylactic Effect of Lamotrigine Compared With Lithium in Bipolar Disorder
Lamotrigine Versus Lithium in Subjects With Bipolar Affective Disorders - a Randomised Study of Prophylactic Effect

The purpose of this study is to compare lamotrigine with lithium in the long term treatment of bipolar disorder in terms of new episode preventive potentials.

Bipolar disorder is a recurrent lifelong illness. Lithium is still the drug of first choice in the prophylactic treatment. However, lithium’s side effects are considerable. Thus the interest in developing alternatives to lithium has increased, and various antiepileptic drugs have been studied. Among these, lamotrigine, which generally is well tolerated, has been evaluated in industry generated trials. However, for various reasons, the generalisability of the results from these studies is limited. Also the follow-up time is limited. This study is a pragmatic effectiveness study, overcoming some of these limitations, and comparing lamotrigine with that of lithium in terms of their potentials for preventing new episodes in patients with bipolar disorder.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Bipolar Disorder
Drug: lithium or lamotrigine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
December 2006
Not Provided

Inclusion criteria:

  1. Age above 18
  2. Inclusion is preceded by an affective episode requiring hospitalisation or outpatient drug treatment (index episode) which can be a manic episode (ICD-10 research criteria), a depressive episode of at least moderate degree (ICD-10 research criteria) or a mixed manic state (manic episode with at least additional three ICD-10 depressive symptoms except for difficulties with concentration or thinking, agitation or dyssomnia). The episode can be with or without psychotic symptoms including Schneiderian first-rank symptoms or bizarre delusions as long as the psychotic symptoms do not occur outside the affective episode.
  3. No more than 12 months may pass between the onset of the index episode (or admission if that is the case)and date of randomisation (in order to ensure a current risk of relapse as well as reliable psychopathological information).
  4. Besides the index episode, at least one previous episode must have occurred within the last five years which meets the criteria mentioned in point number two above. This episode may not necessarily have led to hospitalisation. Two episodes are separated by at least two months without significant symptoms or change in polarity (depression to mania/mixed mania or vice versa).
  5. At least one manic episode (or mixed manic episode) within the last 5 years.

Exclusion criteria:

  1. Contraindications to the protocol drugs.
  2. Severe somatic disease, e.g. epilepsy, which may interfere with study treatment or effect evaluation.
  3. Pregnancy (or risk of pregnancy).
  4. Subject has prior to randomization received prophylactic treatment with lithium or lamotrigine conducted adequately in the sense of sufficient time and dose and ensuring compliance, and experienced a definite lack of prophylactic effect
  5. An ICD-10 diagnosis of abuse within the last year with a subsequent risk of protocol violation. Therefore, subjects with a secondary abuse can often be included in the study.
  6. Anticipated protocol violation for other reasons.
  7. No written informed consent from the subject can be obtained.
  8. The subject has previously been randomised in the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00226135
2612-1400, 98-rc-316
No
Not Provided
University of Aarhus
  • Stanley Medical Research Institute
  • GlaxoSmithKline
Principal Investigator: Rasmus W Licht, MD, PhD Aarhus University Psychiatric Hospital, Risskov, Denmark
University of Aarhus
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP